Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Net Cash Flow for 9 consecutive years, with -$7.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 149.58% to -$7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$132.2 million through Dec 2025, down 209.21% year-over-year, with the annual reading at -$132.2 million for FY2025, 209.21% down from the prior year.
  • Net Cash Flow hit -$7.8 million in Q4 2025 for Sutro Biopharma, down from $1.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $172.6 million in Q2 2023 to a low of -$153.3 million in Q3 2023.
  • Historically, Net Cash Flow has averaged -$7.4 million across 5 years, with a median of -$903000.0 in 2021.
  • Biggest five-year swings in Net Cash Flow: tumbled 21127.27% in 2021 and later surged 8648.08% in 2022.
  • Year by year, Net Cash Flow stood at -$293000.0 in 2021, then plummeted by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then surged by 225.15% to $15.7 million in 2024, then tumbled by 149.58% to -$7.8 million in 2025.
  • Business Quant data shows Net Cash Flow for STRO at -$7.8 million in Q4 2025, $1.9 million in Q3 2025, and -$42.2 million in Q2 2025.